Bortezomib

Description: Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective. Bortezomib has antitumor activity and inhibits NF-kappaB, which can disrupt the cell cycle and induce apoptosis. Target: Proteasome, Autophagy, Apoptosis, NF-kappaB. Smiles: CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O. References: Benvenuto M, et al. Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells. Sci Rep. 2021 Sep 24,11(1):19051.